Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cryo Cell International (CCEL) EBT Margin (2016 - 2025)

Cryo Cell International (CCEL) has disclosed EBT Margin for 16 consecutive years, with 59.06% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 4856.0% to 59.06% in Q4 2025 year-over-year; TTM through Nov 2025 was 7.4%, a 1617.0% decrease, with the full-year FY2025 number at 7.4%, down 1617.0% from a year prior.
  • EBT Margin was 59.06% for Q4 2025 at Cryo Cell International, down from 15.16% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 22.78% in Q2 2021 to a low of 203.04% in Q4 2023.
  • A 5-year average of 4.19% and a median of 10.95% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: plummeted -21106bps in 2023, then soared 19254bps in 2024.
  • Cryo Cell International's EBT Margin stood at 17.0% in 2021, then surged by 147bps to 8.02% in 2022, then crashed by -2632bps to 203.04% in 2023, then soared by 95bps to 10.5% in 2024, then tumbled by -463bps to 59.06% in 2025.
  • Per Business Quant, the three most recent readings for CCEL's EBT Margin are 59.06% (Q4 2025), 15.16% (Q3 2025), and 7.25% (Q2 2025).